

Emily E Hartwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4855453/publications.pdf>

Version: 2024-02-01

31
papers

750
citations

567144

15
h-index

552653

26
g-index

38
all docs

38
docs citations

38
times ranked

1025
citing authors

#	ARTICLE	IF	CITATIONS
1	Sleep disturbances and pain among individuals with prescription opioid dependence. <i>Addictive Behaviors</i> , 2014, 39, 1537-1542.	1.7	76
2	State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 124-140.	1.1	76
3	A meta-analysis of the efficacy of gabapentin for treating alcohol use disorder. <i>Addiction</i> , 2019, 114, 1547-1555.	1.7	74
4	Substance use disorders and PTSD: An exploratory study of treatment preferences among military veterans. <i>Addictive Behaviors</i> , 2014, 39, 369-373.	1.7	67
5	Differences between treatment-seeking and non-treatment-seeking participants in medication studies for alcoholism: do they matter?. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 703-710.	1.1	58
6	Mindfulness-Based Relapse Prevention for Stimulant Dependent Adults: A Pilot Randomized Clinical Trial. <i>Mindfulness</i> , 2017, 8, 126-135.	1.6	53
7	The relationship between methamphetamine and alcohol use in a community sample of methamphetamine users. <i>Drug and Alcohol Dependence</i> , 2014, 142, 127-132.	1.6	35
8	The Association of Alcohol Severity and Sleep Quality in Problem Drinkers. <i>Alcohol and Alcoholism</i> , 2015, 50, 536-541.	0.9	33
9	Sex moderates stress reactivity in heavy drinkers. <i>Addictive Behaviors</i> , 2013, 38, 2643-2646.	1.7	31
10	Systematic review and meta-analysis of the moderating effect of rs1799971 in <i>OPRM1</i> , the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. <i>Addiction</i> , 2020, 115, 1426-1437.	1.7	27
11	Pharmacogenetics of alcohol use disorder treatments: an update. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 553-564.	1.5	23
12	Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. <i>Pharmacology Biochemistry and Behavior</i> , 2015, 134, 92-98.	1.3	18
13	Efficacy of Combining Varenicline and Naltrexone for Smoking Cessation and Drinking Reduction: A Randomized Clinical Trial. <i>American Journal of Psychiatry</i> , 2021, 178, 818-828.	4.0	18
14	Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 613-623.	1.4	17
15	Sex Differences in the Association Between Internalizing Symptoms and Craving in Methamphetamine Users. <i>Journal of Addiction Medicine</i> , 2016, 10, 395-401.	1.4	16
16	Craving as a DSM-5 Symptom of Alcohol Use Disorder in Non-Treatment Seekers. <i>Alcohol and Alcoholism</i> , 2018, 53, 235-240.	0.9	15
17	Prospective randomized pharmacogenetic study of topiramate for treating alcohol use disorder. <i>Neuropsychopharmacology</i> , 2021, 46, 1407-1413.	2.8	13
18	Survey of Addiction Specialists' Use of Medications to Treat Alcohol Use Disorder. <i>Frontiers in Psychiatry</i> , 2020, 11, 47.	1.3	12

#	ARTICLE	IF	CITATIONS
19	A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 89-96.	1.0	11
20	Neuroimaging findings from an experimental pharmacology trial of naltrexone in heavy drinkers of East Asian descent. <i>Drug and Alcohol Dependence</i> , 2019, 200, 181-190.	1.6	10
21	Genetic liability for substance use associated with medical comorbidities in electronic health records of African and European ancestry individuals. <i>Addiction Biology</i> , 2022, 27, e13099.	1.4	9
22	Relationship between tonic and phasic craving for alcohol. <i>Addictive Behaviors Reports</i> , 2018, 7, 71-74.	1.0	7
23	World Health Organization risk drinking levels as a treatment outcome measure in topiramate trials. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 1664-1671.	1.4	7
24	Combined analysis of the moderating effect of a GRIK1 polymorphism on the effects of topiramate for treating alcohol use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108762.	1.6	7
25	Convergence between the Penn Alcohol Craving Scale and diagnostic interview for the assessment of alcohol craving. <i>Addictive Behaviors Reports</i> , 2019, 10, 100198.	1.0	6
26	Behavioral Economic Demand for Alcohol and Cigarettes in Heavy Drinking Smokers: Evidence of Asymmetric Cross-commodity Reinforcing Value. <i>Nicotine and Tobacco Research</i> , 2021, 23, 748-755.	1.4	5
27	Post-treatment effects of topiramate on alcohol-related outcomes: A combined analysis of two placebo-controlled trials. <i>Addiction Biology</i> , 2022, 27, e13130.	1.4	4
28	Alcohol withdrawal in past-year drinkers with unhealthy alcohol use: Prevalence, characteristics, and correlates in a national epidemiologic survey. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 422-433.	1.4	4
29	Analysis of genetic and clinical factors associated with buprenorphine response. <i>Drug and Alcohol Dependence</i> , 2021, 227, 109013.	1.6	2
30	Unique and joint associations of polygenic risk for major depression and opioid use disorder with endogenous opioid system function. <i>Neuropsychopharmacology</i> , 2022, 47, 1784-1790.	2.8	2
31	Association of topiramate prescribed for any indication with reduced alcohol consumption in electronic health record data. <i>Addiction</i> , 2022, 117, 2826-2836.	1.7	1